Aerie Pharmaceuticals, Inc.
Simbol: AERI
NASDAQ
15.25
USDTržna cena danes
-9.4457
Razmerje P/E
0.2147
Razmerje PEG
753.62M
Kapaciteta MRK
- 0.00%
Donos DIV
Aerie Pharmaceuticals, Inc. (AERI) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 691.88 | 139.8 | 240.4 | 309.2 | |||||||||||
balance-sheet.row.short-term-investments | 504.72 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.net-receivables | 364.41 | 158.8 | 56 | 38.4 | |||||||||||
balance-sheet.row.inventory | 174.37 | 40.4 | 27.1 | 21.1 | |||||||||||
balance-sheet.row.other-current-assets | 56.18 | 16.6 | 8.3 | 7.7 | |||||||||||
balance-sheet.row.total-current-assets | 1286.84 | 355.6 | 331.8 | 376.3 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 290.73 | 74.1 | 68.3 | 58.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 3.98 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 6.32 | 1.6 | 1.9 | 18.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 301.03 | 75.7 | 70.3 | 76.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.account-payables | 34.5 | 8.3 | 8.8 | 12.8 | |||||||||||
balance-sheet.row.short-term-debt | 18.45 | 4.4 | 4.9 | 5.5 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 1253.65 | 256.3 | 210.4 | 188.7 | |||||||||||
Deferred Revenue Non Current | 275.63 | 64.3 | 50.9 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 164.69 | 48 | 39.9 | 65.4 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 1542.75 | 323.7 | 273.6 | 202 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 101.17 | 26.1 | 15.1 | 17.6 | |||||||||||
balance-sheet.row.total-liab | 2036.03 | 448.7 | 378.1 | 285.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.19 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -4645 | -1153.9 | -1079.1 | -896 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.15 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 4198.8 | 1136.7 | 1103.1 | 1063 | |||||||||||
balance-sheet.row.total-stockholders-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1587.87 | - | - | - | |||||||||||
Total Investments | 508.71 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.total-debt | 1272.1 | 260.6 | 215.3 | 194.2 | |||||||||||
balance-sheet.row.net-debt | 1084.93 | 223.5 | 63.7 | 50.2 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 18.4 | 29.5 | 40.1 | 45.1 | |||||||||||
cash-flows.row.change-in-working-capital | 5.69 | -92.6 | 44.9 | -24 | |||||||||||
cash-flows.row.account-receivables | -9.31 | -12.8 | -17.7 | -35.6 | |||||||||||
cash-flows.row.inventory | -15.16 | -12.1 | -5.2 | -10.3 | |||||||||||
cash-flows.row.account-payables | -7.51 | 21.6 | 16.9 | -270.8 | |||||||||||
cash-flows.row.other-working-capital | 37.68 | -89.2 | 50.9 | 292.7 | |||||||||||
cash-flows.row.other-non-cash-items | -0.53 | 1.2 | -0.7 | 9.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.17 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -165.66 | -132.4 | -116.6 | -165.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 151.88 | 117.5 | 192.9 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -7.8 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -18.3 | -18.2 | 73.2 | -183.2 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -8.3 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 2.42 | 3 | -0.9 | 0.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.96 | 0 | 8.3 | 274.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.38 | 3 | -0.9 | 274.8 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -7.75 | -114.4 | 7.6 | -58.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 187.16 | 37.2 | 151.6 | 143.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 194.92 | 151.6 | 143.9 | 202.8 | |||||||||||
cash-flows.row.operating-cash-flow | 7.17 | -99.2 | -64.7 | -150.4 | |||||||||||
cash-flows.row.capital-expenditure | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.free-cash-flow | 2.64 | -102.4 | -67.8 | -160.4 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 213.94 | 194.1 | 83.1 | 69.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 23.52 | 26.8 | 25.3 | 4.8 | |||||||||||
income-statement-row.row.gross-profit | 190.42 | 167.3 | 57.8 | 65.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 87.57 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.operating-expenses | 217.13 | 213.6 | 213.5 | 252.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 240.65 | 240.5 | 238.8 | 257.4 | |||||||||||
income-statement-row.row.interest-income | 0.88 | 0.1 | 2 | 3 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
income-statement-row.row.ebitda-caps | -3.07 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -23.24 | -45.3 | -155.7 | -187.5 | |||||||||||
income-statement-row.row.income-before-tax | -35.23 | -74.2 | -177.9 | -199.7 | |||||||||||
income-statement-row.row.income-tax-expense | 1.32 | 0.6 | 5.2 | -0.1 | |||||||||||
income-statement-row.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 |
Pogosto zastavljeno vprašanje
Kaj je Aerie Pharmaceuticals, Inc. (AERI) skupna sredstva?
Aerie Pharmaceuticals, Inc. (AERI) skupna sredstva so 431391000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 69440000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.862.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -2.211.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -0.385.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -0.233.
Kaj je Aerie Pharmaceuticals, Inc. (AERI) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -74810000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 260643000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 213642000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 54093000.000.